^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HLA-A*02:01

i
Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
Entrez ID:
Related biomarkers:
15d
Intradermal naked DNA vaccination by DNA tattooing for mounting tumor-specific immunity in stage IV melanoma patients: a phase I clinical trial. (PubMed, Oncol Res Treat)
We showed that the developed DNA vaccine, applied using a novel intradermal application strategy, can be administered safely. Further research with improved vaccine formats is required to show possible clinical benefit of DNA vaccination.
P1 data • Journal • Metastases
|
CD8 (cluster of differentiation 8)
|
HLA-A*02:01
1m
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (clinicaltrials.gov)
P1, N=24, Suspended, Fred Hutchinson Cancer Center | Trial completion date: Jul 2025 --> Jul 2028 | Trial primary completion date: Oct 2024 --> Oct 2027
Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
|
HLA-A*02:01
|
fludarabine IV
1m
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=44, Not yet recruiting, Diwakar Davar | Trial completion date: Nov 2028 --> Jun 2029 | Initiation date: Nov 2023 --> Jun 2024 | Trial primary completion date: Nov 2026 --> Jun 2026
Trial completion date • Trial initiation date • Trial primary completion date • Circulating tumor DNA • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HLA-A*02:01
|
Signatera™
|
Kimmtrak (tebentafusp-tebn)
2ms
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas (clinicaltrials.gov)
P1/2, N=50, Completed, Sabine Mueller, MD, PhD | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
Trial completion • Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • H3.3K27M • HLA-A*02 • HLA-A2 positive
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC)
3ms
Phase classification • Combination therapy • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
BRAF mutation • HLA-A*02:01 • HLA-A*02
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • Kimmtrak (tebentafusp-tebn)
4ms
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. (PubMed, Melanoma Res)
Detectable ctDNA at baseline did not correlate with progression. Early response to tebentafusp may be incompletely captured by conventional imaging, leading to a need to consider both tumor morphology and metabolism.
Journal • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02
|
Kimmtrak (tebentafusp-tebn)
5ms
Phase I/II Randomized Trial of Cord Blood-derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=44, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Nov 2023
Enrollment open • Trial initiation date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • fludarabine IV
6ms
Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation (ASH 2023)
Targeting MiHAs HA-1 or HA-2 with TSC-100/ 101 following HCT shows early safety and biomarker evidence of efficacy by completing elimination of all detectable patient hematopoietic cells, normal or malignant, thereby reducing relapse risk. Updated results will be presented at the meeting.
P1 data • IO biomarker
|
TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD33 (CD33 Molecule)
|
TP53 mutation • HLA-A*02:01 • TSC1 mutation • HLA-A*02
|
TSC-100 • TSC-101
6ms
T-Cell Receptor-Engineered T Cells Targeting FLT3-D835 Mutation-Derived Neoantigens in Acute Myeloid Leukemia (ASH 2023)
Taken together, we present novel neoantigens with promise as immunotherapy targets for AML and other hematologic malignancies with FLT3-D835 mutations. Future studies will evaluate the efficacy of Neo-D835H-specific TCR-engineered T-cell-based immunotherapy in vivo in patient-derived xenograft murine model and TCR-based therapeutic approaches targeting other FLT3-TKD mutations.
IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • TRB (T Cell Receptor Beta Locus)
|
FLT3 mutation • FLT3-TKD mutation • FLT3 D835Y • FLT3 D835 • HLA-A*02:01 • HLA-A*02 • FLT3 D835H
6ms
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma (clinicaltrials.gov)
P1b/2, N=113, Completed, Immunocore Ltd | Active, not recruiting --> Completed | N=312 --> 113 | Trial completion date: Nov 2023 --> Jun 2023
Trial completion • Enrollment change • Trial completion date • Combination therapy • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
PD-L1 expression • BRAF mutation • HLA-A*02:01 • HLA-A*02
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • Kimmtrak (tebentafusp-tebn)
6ms
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. (PubMed, N Engl J Med)
This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Journal • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • dacarbazine • Kimmtrak (tebentafusp-tebn)
6ms
C-reactive protein impairs immune response of CD8 T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma. (PubMed, J Immunother Cancer)
We found that CRP impaired immune response of CD8 T cells via FcγRIIb-p38MAPK-ROS signaling pathway. The study casted new insights into the role of CRP in anti-myeloma immunity, providing implications for future immunotherapy in MM.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CRP (C-reactive protein)
|
HLA-A*02:01
6ms
Tumor lysis syndrome induced by tebentafusp. (PubMed, Immunotherapy)
Tebentafusp, a bispecific T-cell receptor fusion protein directed against gp100 and CD3, can improve survival in patients with metastatic uveal melanoma and was recently approved for the treatment of HLA-A*02:01-positive uveal melanoma patients. With adequate therapy, including the application of rasburicase, the patient made a full recovery. It is important to raise awareness of the adverse event profile of this new therapeutic approach among healthcare professionals to promptly recognize and treat side effects.
Journal
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02
|
Kimmtrak (tebentafusp-tebn)
7ms
New P2 trial • Circulating tumor DNA • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HLA-A*02:01
|
Signatera™
|
Kimmtrak (tebentafusp-tebn)
7ms
New P1/2 trial
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • fludarabine IV
7ms
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma (clinicaltrials.gov)
P1b/2, N=312, Active, not recruiting, Immunocore Ltd | Trial completion date: Jan 2025 --> Nov 2023 | Trial primary completion date: Jan 2025 --> Jul 2023 | Recruiting --> Active, not recruiting
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
PD-L1 expression • BRAF mutation • HLA-A*02:01 • HLA-A*02
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • Kimmtrak (tebentafusp-tebn)
7ms
TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (EANO 2023)
In addition to the primary safety objectives, secondary objectives of efficacy (progression-free survival, overall survival) and patient-reported quality of life outcomes will be assessed. Trial sponsor: CureVac SE, Germany.
Clinical • P1 data • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
|
TMB-L • HLA-A*02:01 • HLA-A*02 • IDH wild-type
|
CVGBM
7ms
New P1 trial • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3901961
7ms
TEIPP Immunotherapy in Patients With NSCLC (clinicaltrials.gov)
P1/2, N=24, Recruiting, Erasmus Medical Center | Trial primary completion date: Jul 2023 --> Jul 2024
Trial primary completion date • Metastases
|
CD8 (cluster of differentiation 8)
|
HLA-A*02:01
|
Keytruda (pembrolizumab)
8ms
Treatment of uveal melanoma patients with gemcitabine and treosulfan: a retrospective analysis. (EADV 2023)
Tebentafusp is a relatively new licenced therapy option for HLA-A 02:01 positive advanced uveal melanoma. We conclude that gemcitabine and treosulfan treatment can delay tumour progression. Adjustments to the treatment dose are necessary in case of adverse events under therapy. Further investigations are needed to show which patients benefit from initial dose reduction in the treatment.
Retrospective data
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02
|
gemcitabine • Kimmtrak (tebentafusp-tebn) • Ovastat (treosulfan)
8ms
UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT (CTOS 2023)
Our ongoing study highlights the potential of measles virotherapy to both mediate direct tumor cell lysis, as well as enhance anti-tumor immune response as oncolytic vaccine in multiple sarcoma sub-entities. Currently, we are refining MeV sensitivity signature by integrative transcriptomics and proteomics analysis that may act as a predictive biomarker for the response to measles virotherapy. In an in vitro setting, we demonstrate that an oncolytic MeV vaccine carrying NY-ESO-1 can enhance the T cell-mediated killing of sarcoma cells, thereby providing a successful proof-of-concept for the application of MeV-based oncolytic vaccine.
Oncolytic virus • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CD46 (CD46 Molecule)
|
HLA-A*02:01 • HLA-A*02
8ms
New P2 trial • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
9ms
Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages (ESMO 2023)
Conclusions ImmTAC-mediated redirection of T cells reprograms pro-tumoral M2 macrophages towards anti-tumoral M1 macrophages in vitro and in tebentafusp-treated mUM patients. These results demonstrate how tebentafusp re-shapes the tumor microenvironment to enhance the anti-tumor activity of T cells.
IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CD163 (CD163 Molecule) • IRF4 (Interferon regulatory factor 4) • CD40 (CD40 Molecule) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule)
|
HLA-A*02:01 • HLA-A*02 • CD163 expression • HLA-A2 positive • HLA-A positive
|
Kimmtrak (tebentafusp-tebn)
9ms
Patient-specific HLA-I genotypes predict response to immune checkpoint blockade (ESMO 2023)
Conclusions HLA-A status predicted clinical outcomes of patients receiving ICB. HLA genotyping could be incorporated early into the diagnostic work-up of patients with solid cancers as a predictive and selective biomarker.
Clinical • Checkpoint inhibition • Checkpoint block
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*03 • HLA-A*02:01 • HLA-A*02 • HLA-A2 positive
9ms
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov)
P1, N=73, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jan 2023
Trial completion • Trial completion date
|
CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
9ms
PNOC018: Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (clinicaltrials.gov)
P1, N=12, Not yet recruiting, University of California, San Francisco | Trial completion date: Dec 2028 --> Aug 2029 | Initiation date: May 2023 --> Aug 2023 | Trial primary completion date: Dec 2028 --> Aug 2029
Trial completion date • Trial initiation date • Trial primary completion date
|
HLA-A*02:01 • H3.3K27M
|
cyclophosphamide • fludarabine IV • KIND T
9ms
New P1 trial • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097
10ms
Enrollment open • Metastases
|
TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • NT-175
10ms
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer. (PubMed, Cancer Immunol Res)
Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion and low-dose IL2 (Cohort 1). Patients in Cohort 2 received atezolizumab for up to 1 year (NCT02876510)...This study demonstrates the feasibility and tolerability of an actively personalized ACT directed to multiple defined pHLA cancer targets. Results warrant further evaluation of multi-target ACT approaches using potent high-avidity TCRs.
P1 data • Journal • Metastases
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02
|
Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • IMA101
10ms
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (clinicaltrials.gov)
P2, N=66, Recruiting, Adaptimmune | Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Jun 2023
Enrollment open • Trial initiation date • Combination therapy
|
HLA-A (Major Histocompatibility Complex, Class I, A) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
|
Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
10ms
Clinical • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02
11ms
TEIPP Immunotherapy in Patients With NSCLC (clinicaltrials.gov)
P1/2, N=24, Recruiting, Erasmus Medical Center
New P1/2 trial • Metastases
|
CD8 (cluster of differentiation 8)
|
HLA-A*02:01
|
Keytruda (pembrolizumab)
11ms
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. (PubMed, J Immunother Cancer)
At maximum target doses, the safety of tebentafusp with checkpoint inhibitors was consistent with safety of each individual therapy. Tebentafusp with durvalumab demonstrated promising efficacy in heavily pretreated patients with mCM, including those who progressed on prior anti-PD(L)1.
P1 data • Journal • Combination therapy • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HLA-A*02:01 • HLA-A*02
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • Kimmtrak (tebentafusp-tebn)
11ms
New P1 trial • Metastases
|
TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • NT-175
12ms
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. (PubMed, J Immunother Cancer)
ACT of NY-ESO-1 transgenic T cells given with DC vaccination and anti-PD-1 therapy resulted in transient antitumor activity. NY-ESO-1 expression was lost in the post-treatment sample in the setting of extensive methylation of the NY-ESO-1 promoter region.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01 • HLA-A*02 • CTAG1B expression
|
Opdivo (nivolumab)
1year
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. (PubMed, Drugs Today (Barc))
The low current treatment efficacy for mUM, alongside a poor long-term prognosis and high mortality rates, gives precedence for the approval of tebentafusp to be groundbreaking in its clinical impact. This review will discuss the pharmacodynamic and pharmacokinetic profile, and the clinical trials used to evaluate the safety and efficacy of tebentafusp.
Journal • Metastases
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
|
HLA-A*02:01 • HLA-A*02
|
Kimmtrak (tebentafusp-tebn)
1year
Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma. (PubMed, Eur J Immunol)
More importantly, in vivo assays demonstrated greater inhibition of HCC cell proliferation by TP53-Y220C (L2) neoantigen-specific CTLs relative to TP53-Y220C neoantigen in zebrafish and NOD/SCID mouse models. The results of this study demonstrate enhanced immunogenicity of the shared TP53-Y220C (L2) neoantigen, which has the potential as dendritic cells or peptide vaccines for multiple cancers.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • HLA-A*02:01 • TP53 expression • TP53 Y220C
1year
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov)
P1/2, N=9, Terminated, Medigene AG | N=92 --> 9 | Trial completion date: Apr 2024 --> Jul 2022 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Jun 2022; The clinical trial is terminated after the completion of phase I without moving to Phase II.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
HLA-A*02:01 • HLA-A*02 • PRAME expression • HLA-A2 positive
|
MDG1011
1year
DIFFERENT RECOVERY PATTERNS OF CMV-SPECIFIC AND WT1-SPECIFIC T CELLS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLO-HSCT: IMPACT OF CMV INFECTION AND LEUKEMIA RELAPSE (EBMT 2023)
Our results support that CMV reactivation, aside from the CMV-CTL reconstitution, could influence WT1-CTL reconstitution after allo-HSCT, thus potentially contributing to the remission/relapse of AML.
Clinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • WT1 (WT1 Transcription Factor) • BIRC5 (Baculoviral IAP repeat containing 5) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
HLA-A*02:01 • IFNG expression • WT1 expression • WT1 positive
over1year
Trial completion date
|
CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
over1year
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 (clinicaltrials.gov)
P1, N=127, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
Trial completion
|
CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01
|
Opdivo (nivolumab)
over1year
ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=67 --> 11 | Trial completion date: Feb 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Dec 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132